Completed

A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

AR Antagonist (BMS-641988)

Drug
Who is being recruted

Urogenital Diseases+7

+ Genital Diseases

+ Genital Diseases, Male

Over 18 Years
+12 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 1
Interventional
Study Start: May 2006
See protocol details

Summary

Principal SponsorBristol-Myers Squibb
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: May 1, 2006

Actual date on which the first participant was enrolled.

This is a Phase I Dose-Escalation Study of BMS641988 in Patients with Castration-Resistant Prostate Cancer.

Official TitleA Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer
NCT00326586
Principal SponsorBristol-Myers Squibb
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

54 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Male

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesGenital Diseases, MaleGenital Neoplasms, MaleNeoplasmsNeoplasms by SiteProstatic DiseasesProstatic NeoplasmsUrogenital NeoplasmsMale Urogenital Diseases

Criteria

5 inclusion criteria required to participate
Advanced castration-resistant prostate carcinoma with progressive disease
At least 4 weeks must have elapsed from major surgery
Patient must be available for follow-up
Adequate liver and kidney function
Show More Criteria
7 exclusion criteria prevent from participating
Uncontrolled or significant heart disease
History of seizures
History of head injury, loss of consciousness, or stroke
Patients undergoing alcohol withdrawal
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 3 locations

Suspended

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins

Baltimore, United StatesOpen Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins in Google Maps
Suspended

Memorial Sloan-Kettering Cancer Center

New York, United States
Suspended

University Of Wisconsin Hospital And Clinics Laboratory

Madison, United States
Completed3 Study Centers